Want to see CNXC full AI Analyst Report?
Top Page
Concentrix
(NASDAQ:CNXC)
Select Model
Select Model
Rating:56Neutral
Price Target:
$26.00
▼(-13.33% Downside)
Action:Reiterated
Date:06/30/26
The score is held back primarily by weakened financial performance (large net losses) and elevated leverage, despite continued positive cash generation. The latest earnings call is a relative positive due to margin/FCF guidance and debt-reduction plans, but near-term revenue growth remains pressured. Valuation is mixed: a high dividend yield helps, while a negative P/E reflects ongoing losses. Technicals are scored near-neutral due to missing indicator data.
Positive Factors
Revenue Scale
Concentrix's roughly $10B trailing‑12‑month revenue and sustained multi‑year expansion provide durable scale across industries. That scale supports diversified client exposure, supplier and pricing leverage, and the ability to invest in technology and global delivery to sustain long‑term contract wins and resilience.
Negative Factors
Elevated Leverage
Debt‑to‑equity near 1.7 alongside declining equity and recent large net losses reduces financial flexibility. Elevated leverage increases sensitivity to cash‑flow swings, raises refinancing and interest burdens, and limits capacity for opportunistic investments or absorbing further industry shocks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale
Concentrix's roughly $10B trailing‑12‑month revenue and sustained multi‑year expansion provide durable scale across industries. That scale supports diversified client exposure, supplier and pricing leverage, and the ability to invest in technology and global delivery to sustain long‑term contract wins and resilience.
Read all positive factors
Concentrix (CNXC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.53B
Dividend Yield3.38%
Average Volume (3M)1.58M
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth3.81%
EPS Growth-636.38%
CountryUS
Employees450,000
SectorTechnology
Sector Strength88
IndustryInformation Technology Services
Share Statistics
EPS (TTM)-21.55
Shares Outstanding61,004,826
10 Day Avg. Volume1,809,473
30 Day Avg. Volume1,582,339
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.84
Price to Sales (P/S)0.23
P/FCF Ratio4.02
Enterprise Value/Market Cap3.98
Enterprise Value/Revenue0.61
Enterprise Value/Gross Profit1.86
Enterprise Value/Ebitda-19.90
Forecast
1Y Price Target
$32.75Price Target Upside9.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)11.71
Revenue Forecast (FY)$10.11B
Concentrix Business Overview & Revenue Model
Company Description
Concentrix Corporation operates globally, specializing in providing technology-enhanced solutions to optimize customer experiences (CX). The company's services encompass a wide array of offerings, including streamlining CX processes, driving techn...
How the Company Makes Money
Concentrix primarily makes money by providing outsourced CX and business process services to enterprise clients under contracted arrangements. Revenue is largely generated from service fees tied to delivering client programs—commonly priced using ...
Concentrix Earnings Call Summary
Earnings Call Date:Jun 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Sep 30, 2026
Earnings Call Sentiment Neutral
The call balanced strong operational and financial positives—rapid IX suite adoption (400% increase in deals YoY), meaningful productivity gains, record Q2 free cash flow, margin expansion and active debt reduction—against material near-term revenue headwinds from accelerated offshoring (now ~300 bps headwind), client reprioritization, and higher restructuring costs. Management expressed confidence in margin expansion in H2, continued free cash flow generation, and longer-term upside from AI-driven offerings, but acknowledged that revenue growth near-term is muted and that duplicate costs and restructuring will pressure near-term results.Positive Updates
IX Suite Deal Momentum
Closed almost 100 IX suite deals in Q2; number of IX deals up 400% year-over-year; deals selling technology with services up 25% YoY; deals selling AI and technology with services up 80% YoY.
Negative Updates
Revenue Growth Below Prior Expectations
Q2 constant currency growth came in at 0.6% (nearly 2% reported), slightly below guidance; full-year revenue guidance reduced to $9.925B–$10.025B implying constant currency growth of 0.25%–1.25% (a downward revision from prior expectations).
Read all updates
Q2-2026 Updates
Positive
Negative
IX Suite Deal Momentum
Closed almost 100 IX suite deals in Q2; number of IX deals up 400% year-over-year; deals selling technology with services up 25% YoY; deals selling AI and technology with services up 80% YoY.
Read all positive updates
Company Guidance
The company guided Q3 revenue of $2.465–$2.490 billion (≈0–1% constant‑currency growth, with ~75 bps negative FX impact), Q3 non‑GAAP operating income of $295–$305 million (12.0%–12.2% margin), Q3 non‑GAAP EPS of $2.65–$2.77 (assuming ~$65 million interest expense, 60.9 million diluted shares and ~4.8% to participating securities) and a Q3 non‑GAAP tax rate of ~25%; for full‑year FY26 it guided revenue of $9.925–$10.025 billion (≈0.25%–1.25% constant‑currency growth, ~75 bps positive FX impact), non‑GAAP operating income of $1.20–$1.23 billion (12.1%–12.3% margin), non‑GAAP EPS of $10.83–$11.18 (assuming ~$265 million interest expense, 61.1 million diluted shares and ~4.8% to participating securities) and a ~24.5% tax rate, plus adjusted free cash flow of $630–$650 million (guidance is after restructuring), an expectation to repay >$550 million of debt in FY26 and reduce net debt to ~ $3.8 billion (target net leverage <2.0x adjusted EBITDA by year‑end), with Q2 liquidity/cash and debt as of quarter‑end of ~$1.5 billion liquidity ($263 million cash) and ~$4.585 billion total debt and a total FY26 restructuring program of $175 million (including ~$45 million in Q3 and ~$30 million in Q4).Concentrix Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
43
Neutral
Cash Flow
62
Positive
| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.95B | 9.83B | 9.62B | 7.11B | 6.32B | 5.59B |
| Gross Profit | 3.27B | 3.44B | 3.45B | 2.58B | 2.26B | 1.97B |
| EBITDA | -305.24M | -241.77M | 1.33B | 997.53M | 984.62M | 855.92M |
| Net Income | -1.33B | -1.28B | 251.22M | 313.84M | 435.05M | 405.58M |
Balance Sheet | ||||||
| Total Assets | 10.67B | 10.76B | 11.99B | 12.49B | 6.67B | 5.05B |
| Cash, Cash Equivalents and Short-Term Investments | 222.70M | 327.35M | 429.60M | 516.49M | 157.46M | 183.01M |
| Total Debt | 4.75B | 4.64B | 5.60B | 5.79B | 2.72B | 1.31B |
| Total Liabilities | 7.89B | 8.02B | 7.95B | 8.35B | 3.97B | 2.43B |
| Stockholders Equity | 2.79B | 2.74B | 4.04B | 4.14B | 2.70B | 2.62B |
Cash Flow | ||||||
| Free Cash Flow | 484.56M | 572.47M | 428.73M | 497.48M | 460.70M | 365.10M |
| Operating Cash Flow | 722.34M | 806.97M | 667.49M | 678.01M | 600.72M | 514.18M |
| Investing Cash Flow | -249.85M | -250.38M | -244.27M | -2.11B | -1.84B | -78.65M |
| Financing Cash Flow | -575.24M | -491.44M | -492.53M | 1.80B | 1.24B | -401.87M |
Concentrix Technical Analysis
Negative
30.00
Price Trends
25.81
Negative
28.40
Negative
35.00
Negative
Market Momentum
-0.60
Positive
47.14
Neutral
25.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNXC, the sentiment is Negative. The current price of 30 is above the 20-day moving average (MA) of 26.36, above the 50-day MA of 25.81, and below the 200-day MA of 35.00, indicating a bearish trend. The MACD of -0.60 indicates Positive momentum. The RSI at 47.14 is Neutral, neither overbought nor oversold. The STOCH value of 25.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNXC.
Concentrix Risk Analysis
Concentrix disclosed 28 risk factors in its most recent earnings report. Concentrix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Concentrix Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $18.97B | 8.40 | 14.79% | 1.46% | 6.55% | -3.10% | |
71 Outperform | $4.84B | 8.44 | 22.44% | 1.41% | 6.47% | 10.82% | |
71 Outperform | $44.64B | 13.33 | 31.77% | 2.58% | 4.85% | 6.19% | |
68 Neutral | $4.22B | 11.43 | 10.67% | ― | 14.21% | -2.92% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
56 Neutral | $1.53B | -1.18 | -37.51% | 3.38% | 3.81% | -636.38% |
* Technology Sector Average
CNXC
Concentrix
25.23
-25.76
-50.52%
CTSH
Cognizant
38.74
-37.68
-49.30%
EPAM
Epam Systems
80.03
-96.79
-54.74%
G
Genpact
27.85
-15.36
-35.55%
INFY
Infosys
10.70
-7.27
-40.44%
Concentrix Corporate Events
Executive/Board ChangesRegulatory Filings and Compliance
Concentrix Board Sees Director Resignation as GBL Stake Falls
Neutral
May 1, 2026
Concentrix disclosed that under a March 29, 2023 investor rights agreement, Groupe Bruxelles Lambert, a former shareholder of Webhelp’s parent Marnix Lux SA, held the right to appoint one director to the Concentrix board as long as it retain...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.